Axitinib, trade name Inlyta, a tyrosine kinase inhibitor, was approved, by the FDA, for the treatment of metastatic kidney cancer patients after failure of a prior treatment. Approval was granted on January 27, 2012 based on the results of the Phase III AXIS trial comparing axitinib\u2019s superior performance over sorafenib (Nexavar) with respect to progression-free survival. Axitinib was also approved by the European counterpart to the U.S. FDA, the European Medicines Agency (EMA), on September 13, 2012, based on the same trial.<\/p>\n
We are presenting our review of this trial, the results of which were presented at the ASCO 2011 General Meeting by Dr. Brian Rini of the Cleveland Clinic. We also include a review of the survival analysis for axitinib that was presented at the same conference by Dr. Robert Motzer of Memorial Sloan-Kettering.<\/p>\n","protected":false},"excerpt":{"rendered":"
Axitinib, trade name Inlyta, a tyrosine kinase inhibitor, was approved, by the FDA, for the treatment of metastatic kidney cancer patients after failure of a prior treatment. Approval was granted on January 27, 2012 based on the results of the Phase III AXIS trial comparing axitinib\u2019s superior performance over sorafenib (Nexavar) with respect to progression-free survival. Axitinib was also approved by the European counterpart to the U.S. FDA, the European Medicines Agency (EMA), on September… More \u2192<\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"class_list":["post-2815","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/pages\/2815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/comments?post=2815"}],"version-history":[{"count":2,"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/pages\/2815\/revisions"}],"predecessor-version":[{"id":2818,"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/pages\/2815\/revisions\/2818"}],"wp:attachment":[{"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/media?parent=2815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}